Children's Hospital Los Angeles, 4650 Sunset Blvd, Los Angeles, CA 90027, USA.
J Extra Corpor Technol. 2024 Sep;56(3):125-127. doi: 10.1051/ject/2024021. Epub 2024 Sep 20.
The safe use of cardiopulmonary bypass (CPB) relies upon the ability to administer, monitor, and reverse anticoagulation. Although rare, the factor XII deficient patient creates a challenge for the perfusionist due to resultant complications in monitoring anticoagulation. There have been proposed strategies to aid in monitoring anticoagulation in factor XII deficient patients, however, documentation of successful monitoring during CPB is infrequent. With the use of the Hemochron Signature Elite and ACT + cartridges, CPB in a factor XII deficient 8-month-old was completed with predictable and reliable anticoagulation monitoring. This case report explores the current suggestions for factor XII deficiency management with CPB.
体外循环(CPB)的安全使用依赖于给药、监测和逆转抗凝的能力。尽管很少见,但由于监测抗凝时出现的并发症,因子 XII 缺乏症患者给灌注师带来了挑战。已经提出了一些策略来帮助监测因子 XII 缺乏症患者的抗凝,但在 CPB 期间成功监测的记录很少。使用 Hemochron Signature Elite 和 ACT+ 试剂盒,对一名因子 XII 缺乏的 8 个月大的婴儿进行 CPB,抗凝监测可预测且可靠。本病例报告探讨了 CPB 中因子 XII 缺乏症管理的当前建议。